Smart scan could personalize breast cancer care
NCT ID NCT06195709
First seen Jan 11, 2026 · Last updated Jun 19, 2026 · Updated 28 times
Summary
This Phase 3 trial tests whether a special PET scan (EstroTEP) and blood tests can help doctors choose the best second-line treatment for people with ER-positive, HER2-negative metastatic breast cancer. The study will enroll 300 participants and compare outcomes when treatment is guided by these tests versus standard care. The goal is to see if this approach improves how long patients live without their cancer getting worse.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Bruno MAUCHERAT
WITHDRAWNSaint-Herblain, 44805, France
-
CHU Limoges
NOT_YET_RECRUITINGLimoges, 87000, France
Contact Email: •••••@•••••
-
Centre Antoine lacassagne
RECRUITINGNice, 06189, France
Contact Email: •••••@•••••
-
Centre Eugène Marquis
RECRUITINGRennes, 35042, France
Contact Email: •••••@•••••
-
Centre Francois Baclesse
RECRUITINGCaen, 14076, France
Contact Email: •••••@•••••
-
Centre Georges Francois Leclerc
RECRUITINGDijon, 21079, France
Contact Email: •••••@•••••
-
Centre Henri Becquerel
NOT_YET_RECRUITINGRouen, 76038, France
Contact Email: •••••@•••••
-
Centre Hospitalier de la Côte basque
NOT_YET_RECRUITINGBayonne, 64100, France
Contact Email: •••••@•••••
-
Centre Leon Bérard
NOT_YET_RECRUITINGLyon, 69008, France
Contact Email: •••••@•••••
-
Centre Oscar Lambret
RECRUITINGLille, 59000, France
Contact Email: •••••@•••••
-
Centre de lutte contre le cancer Paul Strauss
NOT_YET_RECRUITINGStrasbourg, France
Contact Email: •••••@•••••
-
Hôpital Bretonneau-CHU Tours
NOT_YET_RECRUITINGTours, 37044, France
Contact Email: •••••@•••••
-
Hôpital Universitaire de Nimes
NOT_YET_RECRUITINGNîmes, 30029, France
Contact Email: •••••@•••••
-
Institut Bergonié
NOT_YET_RECRUITINGBordeaux, 33076, France
Contact Email: •••••@•••••
-
Institut Curie
RECRUITINGParis, 75005, France
Contact Email: •••••@•••••
-
Institut Curie
RECRUITINGSaint-Cloud, 92210, France
Contact Email: •••••@•••••
-
Institut Paoli-Calmettes
RECRUITINGMarseille, 13009, France
Contact Email: •••••@•••••
-
Institut de Cancerologie de Lorraine
RECRUITINGVandœuvre-lès-Nancy, 54519, France
Contact Email: •••••@•••••
-
Institut du Cancer Montpellier
RECRUITINGMontpellier, 34298, France
Contact Email: •••••@•••••
-
Oncopole Claudius Regaud
NOT_YET_RECRUITINGToulouse, 31059, France
Contact Email: •••••@•••••
-
Polyclinique Bordeaux Nord Aquitaine
NOT_YET_RECRUITINGBordeaux, 33077, France
Contact Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EstroTEP (18F-FES PET/CT scan) and circulating tumor biomarkers
What this could lead to
If successful, this could show that using a special scan and blood tests helps doctors choose the best treatment for each patient, potentially improving outcomes.
What could go wrong
This is a strategy trial, not testing a new drug, so it may not lead to a direct treatment. Results depend on how well the scan predicts response, and the study is still recruiting.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.